{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:06:25Z","timestamp":1792821985340,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T00:00:00Z","timestamp":1581638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T00:00:00Z","timestamp":1581638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    While the past decade has seen meaningful improvements in clinical outcomes for multiple myeloma patients, a subset of patients does not benefit from current therapeutics for unclear reasons. Many gene expression-based models of risk have been developed, but each model uses a different combination of genes and often involves assaying many genes making them difficult to implement. We organized the Multiple Myeloma DREAM Challenge, a crowdsourced effort to develop models of rapid progression in newly diagnosed myeloma patients and to benchmark these against previously published models. This effort lead to more robust predictors and found that incorporating specific demographic and clinical features improved gene expression-based models of high risk. Furthermore, post-challenge analysis identified a novel expression-based risk marker,\n                    <jats:italic>PHF19<\/jats:italic>\n                    , which has recently been found to have an important biological role in multiple myeloma. Lastly, we show that a simple four feature predictor composed of age, ISS, and expression of\n                    <jats:italic>PHF19<\/jats:italic>\n                    and\n                    <jats:italic>MMSET<\/jats:italic>\n                    performs similarly to more complex models with many more gene expression features included.\n                  <\/jats:p>","DOI":"10.1038\/s41375-020-0742-z","type":"journal-article","created":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T13:03:46Z","timestamp":1581685426000},"page":"1866-1874","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease"],"prefix":"10.1038","volume":"34","author":[{"name":"Multiple Myeloma DREAM Consortium","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5652-7739","authenticated-orcid":false,"given":"Mike J.","family":"Mason","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Schinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine L. P.","family":"Eng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Towfic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6482-8654","authenticated-orcid":false,"given":"Andrew","family":"Dervan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2954-4410","authenticated-orcid":false,"given":"Brian S.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3323-6250","authenticated-orcid":false,"given":"Aditya","family":"Pratapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanfang","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bailiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Chaibub Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Mavrommatis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeriy","family":"Lyzogubov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamlesh","family":"Bisht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyue Y.","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Flynt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Dan Rozelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5669-414X","authenticated-orcid":false,"given":"Samuel A.","family":"Danziger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Ratushny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William S.","family":"Dalton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve","family":"Avet-Loiseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Samur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Hayete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth H.","family":"Shain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Munshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Auclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Hose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Trotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Bassett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0825-4991","authenticated-orcid":false,"given":"Jonathan","family":"Goke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8615-6254","authenticated-orcid":false,"given":"Brian A.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjan","family":"Thakurta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1477-1888","authenticated-orcid":false,"given":"Justin","family":"Guinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,14]]},"reference":[{"key":"742_CR1","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K. Multiple myeloma. N. Engl J Med. 2011;364:1046\u201360.","journal-title":"N. Engl J Med"},{"key":"742_CR2","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1002\/cncr.20652","volume":"101","author":"RA Kyle","year":"2004","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton LJ 3rd. Incidence of multiple myeloma in Olmsted County, Minnesota: trend over 6 decades. Cancer. 2004;101:2667\u201374.","journal-title":"Cancer."},{"key":"742_CR3","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1056\/NEJMra041875","volume":"351","author":"RA Kyle","year":"2004","unstructured":"Kyle RA, Rajkumar SV. Multiple myeloma. N. Engl J Med. 2004;351:1860\u201373.","journal-title":"N. Engl J Med"},{"key":"742_CR4","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","volume":"127","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127:2955\u201362.","journal-title":"Blood."},{"key":"742_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.64","volume":"6","author":"Y Jethava","year":"2016","unstructured":"Jethava Y, Mitchell A, Zangari M, Waheed S, Schinke C, Thanendrarajan S, et al. Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma. Blood Cancer J. 2016;6:e453.","journal-title":"Blood Cancer J."},{"key":"742_CR6","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nrc.2017.63","volume":"17","author":"C Pawlyn","year":"2017","unstructured":"Pawlyn C, Morgan GJ. Evolutionary biology of high-risk multiple myeloma. Nat Rev Cancer. 2017;17:543\u201356.","journal-title":"Nat Rev Cancer"},{"key":"742_CR7","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","volume":"109","author":"JD Shaughnessy Jr","year":"2007","unstructured":"Shaughnessy JD Jr, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109:2276\u201384.","journal-title":"Blood."},{"key":"742_CR8","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1200\/JCO.2010.32.8435","volume":"29","author":"A-L Herv\u00e9","year":"2011","unstructured":"Herv\u00e9 A-L, Florence M, Philippe M, Michel A, Thierry F, Kenneth A, et al. Molecular heterogeneity of multiple myeloma: pathogenesis, prognosis, and therapeutic implications. J Clin Oncol. 2011;29:1893\u20137.","journal-title":"J Clin Oncol"},{"key":"742_CR9","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1182\/blood-2009-12-261032","volume":"116","author":"A Broyl","year":"2010","unstructured":"Broyl A, Hose D, Lokhorst H, de Knegt Y, Peeters J, Jauch A, et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood. 2010;116:2543\u201353.","journal-title":"Blood."},{"key":"742_CR10","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/nbt.1665","volume":"28","author":"L Shi","year":"2010","unstructured":"Shi L, Campbell G, Jones WD, Campagne F, Wen Z, Walker SJ, et al. The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol. 2010;28:827\u201338.","journal-title":"Nat Biotechnol."},{"key":"742_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-016-0906-9","volume":"14","author":"F Kryukov","year":"2016","unstructured":"Kryukov F, Nemec P, Radova L, Kryukova E, Okubote S, Minarik J, et al. Centrosome associated genes pattern for risk sub-stratification in multiple myeloma. J Transl Med. 2016;14:150.","journal-title":"J Transl Med"},{"key":"742_CR12","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1158\/1078-0432.CCR-09-2831","volume":"16","author":"NJ Dickens","year":"2010","unstructured":"Dickens NJ, Walker BA, Leone PE, Johnson DC, Brito JL, Zeisig A, et al. Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome. Clin Cancer Res. 2010;16:1856\u201364.","journal-title":"Clin Cancer Res"},{"key":"742_CR13","doi-asserted-by":"publisher","first-page":"7240","DOI":"10.1158\/1078-0432.CCR-11-1628","volume":"17","author":"T Meissner","year":"2011","unstructured":"Meissner T, Seckinger A, R\u00e8me T, Hielscher T, M\u00f6hler T, Neben K, et al. Gene expression profiling in multiple myeloma-reporting of entities, risk, and targets in clinical routine. Clin Cancer Res. 2011;17:7240\u20137.","journal-title":"Clin Cancer Res"},{"key":"742_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2468","volume":"12","author":"V Popovici","year":"2010","unstructured":"Popovici V, Chen W, Gallas BG, Hatzis C, Shi W, Samuelson FW, et al. Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res. 2010;12:R5.","journal-title":"Breast Cancer Res"},{"key":"742_CR15","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N. Engl J Med. 2017;376:1311\u201320.","journal-title":"N. Engl J Med"},{"key":"742_CR16","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.18632\/oncotarget.1740","volume":"5","author":"A Kassambara","year":"2014","unstructured":"Kassambara A, Gourzones-Dmitriev C, Sahota S, R\u00e8me T, Moreaux J, Goldschmidt H, et al. A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategy. Oncotarget. 2014;5:2487\u201398.","journal-title":"Oncotarget."},{"key":"742_CR17","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1038\/leu.2012.127","volume":"26","author":"R Kuiper","year":"2012","unstructured":"Kuiper R, Broyl A, de Knegt Y, van Vliet MH, van Beers EH, van der Holt B, et al. A gene expression signature for high-risk multiple myeloma. Leukemia. 2012;26:2406\u201313.","journal-title":"Leukemia."},{"key":"742_CR18","first-page":"171","volume":"3","author":"T Liptak","year":"1958","unstructured":"Liptak T. On the combination of independent tests. Magy Tud Akad Mat Kut Int Kozl. 1958;3:171\u201397.","journal-title":"Magy Tud Akad Mat Kut Int Kozl"},{"key":"742_CR19","doi-asserted-by":"publisher","unstructured":"Ren Z, Ahn JH, Liu H, Tsai Y-H, Bhanu NV, Koss B, et al. PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation. Blood. 2019; https:\/\/doi.org\/10.1182\/blood.2019000578","DOI":"10.1182\/blood.2019000578"},{"key":"742_CR20","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","volume":"132","author":"BA Walker","year":"2018","unstructured":"Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies FE, et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018;132:587\u201397.","journal-title":"Blood."},{"key":"742_CR21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","volume":"25","author":"JG Lohr","year":"2014","unstructured":"Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014;25:91\u2013101.","journal-title":"Cancer Cell."},{"key":"742_CR22","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.molcel.2012.11.026","volume":"49","author":"L Cai","year":"2013","unstructured":"Cai L, Rothbart SB, Lu R, Xu B, Chen W-Y, Tripathy A, et al. An H3K36 methylation-engaging Tudor motif of polycomb-like proteins mediates PRC2 complex targeting. Mol Cell. 2013;49:571\u201382.","journal-title":"Mol Cell."},{"key":"742_CR23","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/ni.3154","volume":"16","author":"W Shi","year":"2015","unstructured":"Shi W, Liao Y, Willis SN, Taubenheim N, Inouye M, Tarlinton DM, et al. Transcriptional profiling of mouse B cell terminal differentiation defines a signature for antibody-secreting plasma cells. Nat Immunol. 2015;16:663\u201373.","journal-title":"Nat Immunol."},{"key":"742_CR24","first-page":"200","volume":"10","author":"F Ning","year":"2018","unstructured":"Ning F, Wang C, Niu S, Xu H, Xia K, Wang N. Transcription factor Phf19 positively regulates germinal center reactions that underlies its role in rheumatoid arthritis. Am J Transl Res. 2018;10:200\u201311.","journal-title":"Am J Transl Res"},{"key":"742_CR25","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1038\/nsmb.2449","volume":"19","author":"GL Brien","year":"2012","unstructured":"Brien GL, Gambero G, O\u2019Connell DJ, Jerman E, Turner SA, Egan CM, et al. Polycomb PHF19 binds H3K36me3 and recruits PRC2 and demethylase NO66 to embryonic stem cell genes during differentiation. Nat Struct Mol Biol. 2012;19:1273\u201381.","journal-title":"Nat Struct Mol Biol"},{"key":"742_CR26","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/nsmb.2434","volume":"19","author":"C Ballar\u00e9","year":"2012","unstructured":"Ballar\u00e9 C, Lange M, Lapinaite A, Martin GM, Morey L, Pascual G, et al. Phf19 links methylated Lys36 of histone H3 to regulation of Polycomb activity. Nat Struct Mol Biol. 2012;19:1257\u201365.","journal-title":"Nat Struct Mol Biol"},{"key":"742_CR27","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/CCO.0000000000000390","volume":"29","author":"M Yamagishi","year":"2017","unstructured":"Yamagishi M, Uchimaru K. Targeting EZH2 in cancer therapy. Curr Opin Oncol. 2017;29:375\u201381.","journal-title":"Curr Opin Oncol"},{"key":"742_CR28","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1182\/blood-2007-06-092122","volume":"111","author":"J Marango","year":"2008","unstructured":"Marango J, Shimoyama M, Nishio H, Meyer JA, Min D-J, Sirulnik A, et al. The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood. 2008;111:3145\u201354.","journal-title":"Blood."},{"key":"742_CR29","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/nature08086","volume":"460","author":"K Nimura","year":"2009","unstructured":"Nimura K, Ura K, Shiratori H, Ikawa M, Okabe M, Schwartz RJ, et al. A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf-Hirschhorn syndrome. Nature. 2009;460:287\u201391.","journal-title":"Nature."},{"key":"742_CR30","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1016\/j.febslet.2009.05.038","volume":"583","author":"H-B Kang","year":"2009","unstructured":"Kang H-B, Choi Y, Lee JM, Choi K-C, Kim H-C, Yoo J-Y, et al. The histone methyltransferase, NSD2, enhances androgen receptor-mediated transcription. FEBS Lett. 2009;583:1880\u20136.","journal-title":"FEBS Lett"},{"key":"742_CR31","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/leu.2017.197","volume":"32","author":"A Lagan\u00e0","year":"2018","unstructured":"Lagan\u00e0 A, Perumal D, Melnekoff D, Readhead B, Kidd BA, Leshchenko V, et al. Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma. Leukemia. 2018;32:120\u201330.","journal-title":"Leukemia."},{"key":"742_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0162-8","volume":"9","author":"M Went","year":"2018","unstructured":"Went M, Sud A, Speedy H, Sunter NJ, F\u00f6rsti A, Law PJ, et al. Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology. Blood Cancer J. 2018;9:1.","journal-title":"Blood Cancer J."},{"key":"742_CR33","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s42003-019-0329-2","volume":"2","author":"S Chattopadhyay","year":"2019","unstructured":"Chattopadhyay S, Thomsen H, Yadav P, da Silva Filho MI, Weinhold N, N\u00f6then MM, et al. Genome-wide interaction and pathway-based identification of key regulators in multiple myeloma. Commun Biol. 2019;2:89.","journal-title":"Commun Biol"},{"key":"742_CR34","doi-asserted-by":"publisher","first-page":"7776","DOI":"10.1158\/1078-0432.CCR-11-1791","volume":"17","author":"KD Boyd","year":"2011","unstructured":"Boyd KD, Ross FM, Walker BA, Wardell CP, Tapper WJ, Chiecchio L, et al. Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clin Cancer Res. 2011;17:7776\u201384.","journal-title":"Clin Cancer Res"},{"key":"742_CR35","doi-asserted-by":"publisher","first-page":"6347","DOI":"10.1158\/1078-0432.CCR-11-0994","volume":"17","author":"P Wu","year":"2011","unstructured":"Wu P, Walker BA, Brewer D, Gregory WM, Ashcroft J, Ross FM, et al. A gene expression-based predictor for myeloma patients at high risk of developing bone disease on bisphosphonate treatment. Clin Cancer Res. 2011;17:6347\u201355.","journal-title":"Clin Cancer Res"},{"key":"742_CR36","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1158\/1535-7163.MCT-12-0721","volume":"11","author":"J Moreaux","year":"2012","unstructured":"Moreaux J, R\u00e8me T, Leonard W, Veyrune J-L, Requirand G, Goldschmidt H, et al. Development of gene expression-based score to predict sensitivity of multiple myeloma cells to DNA methylation inhibitors. Mol Cancer Ther. 2012;11:2685\u201392.","journal-title":"Mol Cancer Ther"},{"key":"742_CR37","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.18632\/oncotarget.3207","volume":"6","author":"K Maes","year":"2015","unstructured":"Maes K, De Smedt E, Kassambara A, Hose D, Seckinger A, Van Valckenborgh E, et al. In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma. Oncotarget. 2015;6:3319\u201334.","journal-title":"Oncotarget."}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0742-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0742-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0742-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:39:27Z","timestamp":1684604367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-0742-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,14]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["742"],"URL":"https:\/\/doi.org\/10.1038\/s41375-020-0742-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/737122","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,14]]},"assertion":[{"value":"10 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Please note the following byline authors: FT, KM, KB, FS, EF, AR, SAD, AD, DB, MT, AT have employment and\/or equity ownership in Celgene. AD also had equity in Twinstrand Biosciences. WSD has employment with M2Gen. HG has research support (Amgen, BMS, Celgene, Chugai, Janssen, Molecular Partners, MSD, Sanofi, Mundipharma, Takeda and Novartis), advisory boards (Adaptive Biotechnology, Amgen, BMS, Celgene, Janssen, Sanofi and Takeda), honoraria (ArtTempi, BMS, Celgene, Chugai, Janssen, Novartis and Sanofi). NM has consulted for Abbvie, Adaptive, Amgen, Celgene, Janssen, Takeda and Oncopep and also has equity in Oncopep. KHS is on advisory boards for: Celgene, BMS, Amgen, Takeda, Janssen and Sanofi Genzyme, has received research funding from AbbVie, and has consulted for Adaptive Biotechnologies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}